JP2012012388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012012388A5 JP2012012388A5 JP2011125191A JP2011125191A JP2012012388A5 JP 2012012388 A5 JP2012012388 A5 JP 2012012388A5 JP 2011125191 A JP2011125191 A JP 2011125191A JP 2011125191 A JP2011125191 A JP 2011125191A JP 2012012388 A5 JP2012012388 A5 JP 2012012388A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- alkyl
- optionally
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 698
- 125000003545 alkoxy group Chemical group 0.000 claims description 195
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 162
- 125000004193 piperazinyl group Chemical group 0.000 claims description 110
- -1 Piperazyl Chemical group 0.000 claims description 88
- 125000002757 morpholinyl group Chemical group 0.000 claims description 84
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 77
- 125000002252 acyl group Chemical group 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 67
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 64
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 60
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 58
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 52
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 38
- 125000003277 amino group Chemical group 0.000 claims description 36
- 125000004414 alkyl thio group Chemical group 0.000 claims description 29
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 25
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 23
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 23
- 125000005936 piperidyl group Chemical group 0.000 claims description 22
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000002541 furyl group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 19
- 125000001544 thienyl group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 125000004423 acyloxy group Chemical group 0.000 claims description 17
- 125000001589 carboacyl group Chemical group 0.000 claims description 14
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 11
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 11
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 10
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 10
- 125000005959 diazepanyl group Chemical group 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 10
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 126
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 27
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 12
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 5
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 208000035172 MERRF Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000002033 Myoclonus Diseases 0.000 claims 2
- 206010028629 Myoglobinuria Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 240000007817 Olea europaea Species 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 2
- 206010042928 Syringomyelia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 230000004898 mitochondrial function Effects 0.000 claims 2
- 230000003387 muscular Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000007658 neurological function Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003252 repetitive effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 102100032533 ADP/ATP translocase 1 Human genes 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002027 Amyotrophy Diseases 0.000 claims 1
- 208000009017 Athetosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035183 Benign hereditary chorea Diseases 0.000 claims 1
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241001112695 Clostridiales Species 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 102100025287 Cytochrome b Human genes 0.000 claims 1
- 108010075028 Cytochromes b Proteins 0.000 claims 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000002603 Dopa-responsive dystonia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- 101000768061 Escherichia phage P1 Antirepressor protein 1 Proteins 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims 1
- 101000796932 Homo sapiens ADP/ATP translocase 1 Proteins 0.000 claims 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000035177 MELAS Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 1
- 208000014844 Mitochondrial neurogastrointestinal encephalomyopathy Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 102100035196 POLG alternative reading frame Human genes 0.000 claims 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010065657 Paroxysmal choreoathetosis Diseases 0.000 claims 1
- 208000013234 Pearson syndrome Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037764 Radiation myelopathy Diseases 0.000 claims 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038422 Renal cortical necrosis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000027919 Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 201000010829 Spina bifida Diseases 0.000 claims 1
- 208000006097 Spinal Dysraphism Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000010123 anthracosis Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 201000003636 hereditary ataxia Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical class 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000005430 kidney cortex necrosis Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 201000002648 nephronophthisis Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 208000001749 optic atrophy Diseases 0.000 claims 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000002916 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UHDUNSWZQSYJFM-UHFFFAOYSA-N CC(C=C1c2ccc[s]2)c(c(nccc2)c2cc2OC)c2C1=O Chemical compound CC(C=C1c2ccc[s]2)c(c(nccc2)c2cc2OC)c2C1=O UHDUNSWZQSYJFM-UHFFFAOYSA-N 0.000 description 1
- 0 CCC*c(c(O)c1C(C(c2c[n]cc2)=C*)O)cc2c1OCC2 Chemical compound CCC*c(c(O)c1C(C(c2c[n]cc2)=C*)O)cc2c1OCC2 0.000 description 1
- BVCSMMZPWMNBHX-UHFFFAOYSA-N CCCOc(c(C(C=C1c(cc2)ccc2OC)=C)c2C1=C)cc1c2OCC1 Chemical compound CCCOc(c(C(C=C1c(cc2)ccc2OC)=C)c2C1=C)cc1c2OCC1 BVCSMMZPWMNBHX-UHFFFAOYSA-N 0.000 description 1
- KXMXMZWNQYZEKV-UHFFFAOYSA-M CCCOc(cc(CCC1)c1c12)c1N(COP([O-])(O)=O)C=C(c(cc1)ccc1OC)C2=O Chemical compound CCCOc(cc(CCC1)c1c12)c1N(COP([O-])(O)=O)C=C(c(cc1)ccc1OC)C2=O KXMXMZWNQYZEKV-UHFFFAOYSA-M 0.000 description 1
- RVTXYORLNGJHDG-UHFFFAOYSA-N CCCOc(cc(c(F)c12)F)c1N(COP(OC(C)(C)C)(OC(C)(C)C)=O)C=C(c(cc1)ccc1OC)C2=O Chemical compound CCCOc(cc(c(F)c12)F)c1N(COP(OC(C)(C)C)(OC(C)(C)C)=O)C=C(c(cc1)ccc1OC)C2=O RVTXYORLNGJHDG-UHFFFAOYSA-N 0.000 description 1
- ZDTKAOQCCWRQKP-UHFFFAOYSA-N CCCOc(ccc(F)c12)c1N(COP(O)(O)=O)C=C(c(cc1)ccc1OC)C2=O Chemical compound CCCOc(ccc(F)c12)c1N(COP(O)(O)=O)C=C(c(cc1)ccc1OC)C2=O ZDTKAOQCCWRQKP-UHFFFAOYSA-N 0.000 description 1
- KQAOEZFARPJDRQ-UHFFFAOYSA-N CCCOc(ccc(F)c12)c1N(COP(OC(C)(C)C)(OC(C)(C)C)=O)C=C(c(c(Cl)c1)ccc1Cl)C2=O Chemical compound CCCOc(ccc(F)c12)c1N(COP(OC(C)(C)C)(OC(C)(C)C)=O)C=C(c(c(Cl)c1)ccc1Cl)C2=O KQAOEZFARPJDRQ-UHFFFAOYSA-N 0.000 description 1
- MNYBFDITJKTSSJ-UHFFFAOYSA-N CN(C1CCCCC1)c(c(N(COP(O)(O)=O)C=C1c(cc2)ccc2OC)c2C1=O)ccc2F Chemical compound CN(C1CCCCC1)c(c(N(COP(O)(O)=O)C=C1c(cc2)ccc2OC)c2C1=O)ccc2F MNYBFDITJKTSSJ-UHFFFAOYSA-N 0.000 description 1
- GVZIKOWKPBXZDU-UHFFFAOYSA-N COC1=CC=C(C=C1)C2=C(C(=CC(=C2)C(=O)O)[P+](=O)[O-])OP(=O)(O)O Chemical compound COC1=CC=C(C=C1)C2=C(C(=CC(=C2)C(=O)O)[P+](=O)[O-])OP(=O)(O)O GVZIKOWKPBXZDU-UHFFFAOYSA-N 0.000 description 1
- WMNZFXMBZZPNFE-UHFFFAOYSA-N COc(cc1)ccc1C(C(c1c(cc2)F)=O)=CN(COP(N)(O)=O)c1c2OCC1CCC1 Chemical compound COc(cc1)ccc1C(C(c1c(cc2)F)=O)=CN(COP(N)(O)=O)c1c2OCC1CCC1 WMNZFXMBZZPNFE-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- ZKBVSKOXBABNKZ-UHFFFAOYSA-N [5-fluoro-3-(4-methoxyphenyl)-4-oxo-8-propoxyquinolin-1-yl]methyl 4-hydroxybenzoate Chemical compound CCCOC1=CC=C(F)C(C(C(C=2C=CC(OC)=CC=2)=C2)=O)=C1N2COC(=O)C1=CC=C(O)C=C1 ZKBVSKOXBABNKZ-UHFFFAOYSA-N 0.000 description 1
- PYXCPXFSPSMOGT-UHFFFAOYSA-N [5-fluoro-3-(4-methoxyphenyl)-4-oxo-8-propoxyquinolin-1-yl]methyl benzoate Chemical compound CCCOC1=CC=C(F)C(C(C(C=2C=CC(OC)=CC=2)=C2)=O)=C1N2COC(=O)C1=CC=CC=C1 PYXCPXFSPSMOGT-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- YGFLCNPXEPDANQ-UHFFFAOYSA-N n-[bis[(2-methylpropan-2-yl)oxy]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(OC(C)(C)C)OC(C)(C)C YGFLCNPXEPDANQ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011125191A JP5769504B2 (ja) | 2010-06-04 | 2011-06-03 | 医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010128756 | 2010-06-04 | ||
| JP2010128756 | 2010-06-04 | ||
| JP2011125191A JP5769504B2 (ja) | 2010-06-04 | 2011-06-03 | 医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012012388A JP2012012388A (ja) | 2012-01-19 |
| JP2012012388A5 true JP2012012388A5 (OSRAM) | 2014-05-08 |
| JP5769504B2 JP5769504B2 (ja) | 2015-08-26 |
Family
ID=45599243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011125191A Expired - Fee Related JP5769504B2 (ja) | 2010-06-04 | 2011-06-03 | 医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5769504B2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623562A (zh) * | 2017-03-24 | 2018-10-09 | 中国海洋大学 | 一种喹啉酮生物碱类化合物及其制备方法和应用 |
| CN108623560A (zh) * | 2017-03-24 | 2018-10-09 | 中国海洋大学 | 一种喹啉酮酸类衍生物及其制备方法和用途 |
| CN112823006B (zh) * | 2018-10-17 | 2024-09-17 | 杜克大学 | 用作神经保护剂的醌还原酶2抑制剂 |
| CA3114462A1 (en) * | 2018-10-17 | 2020-04-23 | Duke University | Quinone reductase 2 inhibitor compounds and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797444B1 (fr) * | 1999-08-13 | 2003-02-07 | Lafon Labor | Compositions pharmaceutiques comprenant des 4-quinolones |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| TWI366565B (en) * | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
| TWI492943B (zh) * | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物（二） |
-
2011
- 2011-06-03 JP JP2011125191A patent/JP5769504B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000128782A (ja) | アニリド誘導体含有ｃｃｒ５拮抗剤 | |
| HU229314B1 (en) | Polymorphs of an epothilone analog | |
| CN103154004A (zh) | 具有hiv整合酶抑制活性的化合物的制造方法 | |
| TW201734001A (zh) | ＲＯＲ－γ調節劑 | |
| EP1658272A1 (en) | Novel gamma-secretase inhibitors | |
| WO2006038594A1 (ja) | Ｎ型カルシウムチャネル阻害薬 | |
| JP2004522792A5 (OSRAM) | ||
| CA3172478A1 (en) | Bcl-2 inhibitor | |
| ES2398934T3 (es) | Proceso de la producción de1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)acetidin-ol o sales del mismo | |
| TW200306809A (en) | Compounds for the treatment of inflammatory disorders | |
| WO2001068607A1 (en) | Amide compounds and use thereof | |
| JP2010536713A5 (OSRAM) | ||
| CN107001286B (zh) | 二氢嘧啶-2-酮化合物和其医药用途 | |
| JP2012012388A5 (OSRAM) | ||
| JP7566753B2 (ja) | 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料 | |
| CA3104956C (en) | Novel lxr modulators with bicyclic core moiety | |
| JP2021059578A (ja) | オキシンドール化合物およびその医薬組成物 | |
| CA2883221C (en) | Benzofurazan anti-amyloid compounds and methods | |
| JP4416198B2 (ja) | アニリド誘導体、その製造法および用途 | |
| CN112654606A (zh) | 三氮唑类化合物及其制备方法与用途 | |
| JP7428833B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
| JP7422741B2 (ja) | ２－［（３ｒ）－３－メチルモルホリン－４－イル］－４－（１－メチル－１ｈ－ピラゾール－５－イル）－８－（１ｈ－ピラゾール－５－イル）－１，７－ナフチリジンを調製する方法 | |
| WO2000023437A1 (en) | Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same | |
| JP2005501800A (ja) | ジヒドロピラゾロピリジン化合物およびその医薬用途 | |
| CN102584512B (zh) | 一种一锅法合成苯并呋喃衍生物的方法 |